Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?-Reference-Cited by-同舟云学术

Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?

Published:2019-10 Issue:6 Volume:51 Page:653-655
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Zaborowski Matthew,Gill Anthony J.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference9 articles.

1. Secretory breast carcinoma: a report of three cases and a review of the literature;Lee;Oncol Lett,2014

2. Breast carcinoma in children;McDivott;JAMA,1966

3. NTRK fusion-positive cancers and TRK inhibitory therapy;Cocco;Nat Rev Clin Oncol,2018

4. Inhibiting TRK proteins in clinical cancer therapy;Lange;Cancers (Basel),2018

5. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma;Journal of Clinical Pathology;2023-08-16

2. Advancement of secretory breast carcinoma: a narrative review;Annals of Translational Medicine;2022-11

3. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis;Cancers;2021-11-14

4. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas;Frontiers in Oncology;2021-04-29

5. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer;Archives of Pathology & Laboratory Medicine;2020-10-28